ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v15i5.1961ppharm-1666Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWПерспективы применения лечебных свойств ксенона в педиатрииProspects for Applying Xenon Curative Properties in Pediatricshttps://orcid.org/0000-0001-9896-1798СабининаТ. С.SabininaTatiana S.https://orcid.org/0000-0003-3773-5185БагаевВ. Г.BagaevVladimir G.

Багаев Владимир Геннадьевич, доктор медицинских наук, старший научный сотрудник отделения анестезиологии и реанимации

119180, Москва, ул. Большая Полянка, д. 22

bagaev61@mail.ruhttps://orcid.org/0000-0002-5823-3574АлексеевИ. Ф.AlekseevIlia F.Научно-исследовательский институт неотложной детской хирургии и травматологииРоссияResearch Institute of Emergency Pediatric Surgery and TraumatologyRussian Federation201824122018155390395Copyright © Сабинина Т.С., Багаев В.Г., Алексеев И.Ф., 20182018Сабинина Т.С., Багаев В.Г., Алексеев И.Ф.Sabinina T.S., Bagaev V.G., Alekseev I.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/1666

Обзор посвящен экспериментальным и клиническим исследованиям применения инертного газа ксенона в лечении терапевтических состояний у взрослых, а также перспективам его применения у детей. Терапевтическое воздействие ксенона на организм основано на лечебных свойствах инертного газа. По анестезирующим свойствам он близок к «идеальному анестетику», но помимо этого обладает органои нейропротективными, а также антистрессорными свойствами, доказанными в эксперименте и клинически. Интерес к применению ксенона в педиатрии продиктован тем, что в терапевтических концентрациях до 30% он не токсичен, эффективен в лечении постгипоксических и травматических поражений центральной нервной системы, болевых синдромов и стрессовых состояний.

The review discusses experimental and clinical trials on applying noble gas Xenon to treat therapeutic conditions in adults, as well as the prospects for its applying in children. Xenon therapeutic effects on the body are based on the healing properties of a noble gas. Xenon is close to the ‘ideal anesthetic’ by its anesthetic properties; but in addition, it possesses organoand neuroprotective as well as anti-stress properties which have been proved in experiment and clinically. Xenon in pediatric practice is an attractive agent because it is non-toxic, effective for the treatment of posthypoxic and traumatic impairments of the central nervous system, pain syndromes and stress conditions at its therapeutic concentration up to 30%.

обезболивание ксенономнейропротекция ксенономантистрессорный эффект ксенонаxenon anesthesiaxenon neuroprotectionxenon antistress effectНе указанNot specifiedReferencesMeyer K., Hemmi H. Beitrage zur theorie der narcose. Biochem Z. 1935;277:1–2.Meyer K., Hemmi H. Beitrage zur theorie der narcose. Biochem Z. 1935;277:1–2.Лазарев Н.В., Люблина Е.И., Мадорская Р.Я. О наркотическом действии ксенона // Физиологический журнал СССР. — 1947. — №34 — С. 131–134.Lazarev NV, Lyublina EI, Madorskaya RYa. O narkoticheskom deistvii ksenona. Fiziologicheskii zhurnal SSSR. 1947;(34):131–134. (In Russ).Cullen SC, Gross EG. The anesthetic properties of xenon in animals and human beings, with additional observations on krypton. Science. 1951;113(2942):580–582.Cullen SC, Gross EG. The anesthetic properties of xenon in animals and human beings, with additional observations on krypton. Science. 1951;113(2942):580–582.Буров Н.Е., Потапов В.Н., Макеев Г.Н. Ксенон в анестезиологии: Клинико-эксперим. исслед. — М.: Пульс; 2000. — 391 с.Burov NE, Potapov VN, Makeev GN. Ksenon v anesteziologii: Klinikoeksperim. issled. Moscow: Pul’s; 2000. 391 р. (In Russ).Lachmann B, Armbruster S, Schairer W, et al. Safety and efficacy of xenon in routine use as an inhalational anaesthetic. Lancet. 1990;335(8703):1413–1415.Lachmann B, Armbruster S, Schairer W, et al. Safety and efficacy of xenon in routine use as an inhalational anaesthetic. Lancet. 1990;335(8703):1413–1415.Багаев В.Г., Амчеславский В.Г., Хмельницкий К.Е., и др. Результаты клинического исследования эффективности и безопасности ЛС «Ксемед» при общей анестезии у детей // Российский вестник неотложной детской хирургии, анестезиологии и реаниматологии. — 2012. — №4 — С. 70–78.Bagaev VG, Amcheslavskii VG, Khmel’nitskii KE, et al. Rezul’taty klinicheskogo issledovaniya effektivnosti i bezopasnosti LS «Ksemed» pri obshchei anestezii u detei. Rossiiskii vestnik neotlozhnoi detskoi khirurgii, anesteziologii i reanimatologii. 2012;(4):70–78. (In Russ).]Stiell IG, Wells GA, Field B, et al. Advanced cardiac life support in out-of-hospital cardiac arrest. N Engl J Med. 2004;351(7):647–656. doi: 10.1056/NEJMoa040325.Stiell IG, Wells GA, Field B, et al. Advanced cardiac life support in out-of-hospital cardiac arrest. N Engl J Med. 2004;351(7):647–656. doi: 10.1056/NEJMoa040325.Hallstrom AP, Ornato JP, Weisfeldt M, et al. Public-access defibrillation and survival after out-of-hospital cardiac arrest. N Engl J Med. 2004;351(7):637–646. doi: 10.1056/NEJMoa040566.Hallstrom AP, Ornato JP, Weisfeldt M, et al. Public-access defibrillation and survival after out-of-hospital cardiac arrest. N Engl J Med. 2004;351(7):637–646. doi: 10.1056/NEJMoa040566.Hopkins RO, Jackson JC. Long-term neurocognitive function after critical illness. Chest. 2006;130(3):869–878. doi: 10.1378/chest.130.3.869.Hopkins RO, Jackson JC. Long-term neurocognitive function after critical illness. Chest. 2006;130(3):869–878. doi: 10.1378/chest.130.3.869.Fries M, Nolte KW, Coburn M, et al. Xenon reduces neurohistopathological damage and improves the early neurological deficit after cardiac arrest in pigs. Crit Care Med. 2008;36(8):2420– 2426. doi: 10.1097/CCM.0b013e3181802874.Fries M, Nolte KW, Coburn M, et al. Xenon reduces neurohistopathological damage and improves the early neurological deficit after cardiac arrest in pigs. Crit Care Med. 2008;36(8):2420– 2426. doi: 10.1097/CCM.0b013e3181802874.Xiang Z, Yuan M, Hassen GW, et al. Lactate induced excitotoxicity in hippocampal slice cultures. Exp Neurol. 2004;186(1):70–77. doi: 10.1016/j.expneurol.2003.10.015.Xiang Z, Yuan M, Hassen GW, et al. Lactate induced excitotoxicity in hippocampal slice cultures. Exp Neurol. 2004;186(1):70–77. doi: 10.1016/j.expneurol.2003.10.015.Smith WS. Pathophysiology of focal cerebral ischemia: a therapeutic perspective. J Vasc Interv Radiol. 2004;15(1 Pt 2):S3– 12. doi: 10.1097/01.rvi.0000108687.75691.0c.Smith WS. Pathophysiology of focal cerebral ischemia: a therapeutic perspective. J Vasc Interv Radiol. 2004;15(1 Pt 2):S3– 12. doi: 10.1097/01.rvi.0000108687.75691.0c.Dinse A, Föhr KJ, Georgieff M, et al. Xenon reduces glutamate-, AMPA-, and kainate-induced membrane currents in cortical neurones. Br J Anaesth. 2005;94(4):479–485. doi: 10.1093/bja/aei080.Dinse A, Föhr KJ, Georgieff M, et al. Xenon reduces glutamate-, AMPA-, and kainate-induced membrane currents in cortical neurones. Br J Anaesth. 2005;94(4):479–485. doi: 10.1093/bja/aei080.Chakkarapani E, Thoresen M, Hobbs CE, et al. A closedcircuit neonatal xenon delivery system: a technical and practical neuroprotection feasibility study in newborn pigs. Anesth Analg. 2009;109(2):451–460. doi: 10.1213/ane.0b013e3181aa9550.Chakkarapani E, Thoresen M, Hobbs CE, et al. A closedcircuit neonatal xenon delivery system: a technical and practical neuroprotection feasibility study in newborn pigs. Anesth Analg. 2009;109(2):451–460. doi: 10.1213/ane.0b013e3181aa9550.Natale G, Cattano D, Abramo A, et al. Morphological evidence that xenon neuroprotects against N-methyl-DL-aspartic acid-induced damage in the rat arcuate nucleus: a time-dependent study. Ann N Y Acad Sci. 2006;1074:650–658. doi: 10.1196/annals.1369.063.Natale G, Cattano D, Abramo A, et al. Morphological evidence that xenon neuroprotects against N-methyl-DL-aspartic acid-induced damage in the rat arcuate nucleus: a time-dependent study. Ann N Y Acad Sci. 2006;1074:650–658. doi: 10.1196/annals.1369.063.Esencan E, Yuksel S, Tosun YB, et al. Xenon in medical area: emphasis on neuroprotection in hypoxia and anesthesia. Med Gas Res. 2013;3(1):4. doi: 10.1186/2045-9912-3-4.Esencan E, Yuksel S, Tosun YB, et al. Xenon in medical area: emphasis on neuroprotection in hypoxia and anesthesia. Med Gas Res. 2013;3(1):4. doi: 10.1186/2045-9912-3-4.Rizvi M, Jawad N, Li Y, et al. Effect of noble gases on oxygen and glucose deprived injury in human tubular kidney cells. Exp Biol Med. 2010;235(7):886–891. doi: 10.1258/ebm.2010.009366.Rizvi M, Jawad N, Li Y, et al. Effect of noble gases on oxygen and glucose deprived injury in human tubular kidney cells. Exp Biol Med. 2010;235(7):886–891. doi: 10.1258/ebm.2010.009366.Smith WS. Pathophysiology of focal cerebral ischemia: a therapeutic perspective. J Vasc Interv Radiol. 2004;15(1 Pt 2):S3– 12. doi: 10.1097/01.rvi.0000108687.75691.0c.Smith WS. Pathophysiology of focal cerebral ischemia: a therapeutic perspective. J Vasc Interv Radiol. 2004;15(1 Pt 2):S3– 12. doi: 10.1097/01.rvi.0000108687.75691.0c.Sanders RD, Maze M. Xenon: from stranger to guardian. Curr Opin Anaesthesiol. 2005;18(4):405–411. doi: 10.1097/01.aco.0000174957.97759.f6.Sanders RD, Maze M. Xenon: from stranger to guardian. Curr Opin Anaesthesiol. 2005;18(4):405–411. doi: 10.1097/01.aco.0000174957.97759.f6.Zhu C, Qiu L, Wang X, et al. Involvement of apoptosis-inducing factor in neuronal death after hypoxia-ischemiain the neonatal rat brain. J Neurochem. 2003;86(2):306–317.Zhu C, Qiu L, Wang X, et al. Involvement of apoptosis-inducing factor in neuronal death after hypoxia-ischemiain the neonatal rat brain. J Neurochem. 2003;86(2):306–317.Yıldız EP, Ekici B, Tatlı B. Neonatal hypoxic ischemic encephalopathy: an update on disease pathogenesis and treatment. Expert Rev Neurother. 2017;17(5):449–459. doi: 10.1080/14737175.2017.1259567.Yıldız EP, Ekici B, Tatlı B. Neonatal hypoxic ischemic encephalopathy: an update on disease pathogenesis and treatment. Expert Rev Neurother. 2017;17(5):449–459. doi: 10.1080/14737175.2017.1259567.Luo Y, Ma D, Ieong E, et al. Xenon and sevoflurane protect against brain injury in a neonatal asphyxia model. Anesthesiology. 2008;109(5):782–789. doi: 10.1097/ALN.0b013e3181895f88.Luo Y, Ma D, Ieong E, et al. Xenon and sevoflurane protect against brain injury in a neonatal asphyxia model. Anesthesiology. 2008;109(5):782–789. doi: 10.1097/ALN.0b013e3181895f88.Dworschak M. Pharmacologic neuroprotection — is xenon the light at the end of the tunnel? Crit Care Med. 2008;36(8):2477– 2479. doi: 10.1097/CCM.0b013e31818113d2.Dworschak M. Pharmacologic neuroprotection — is xenon the light at the end of the tunnel? Crit Care Med. 2008;36(8):2477– 2479. doi: 10.1097/CCM.0b013e31818113d2.Dingley J, Tooley J, Porter H, Thoresen M. Xenon provides shortterm neuroprotection in neonatal rats when administered after hypoxia-ischemia. Stroke. 2006;37(2):501–506. doi: 10.1161/01.STR.0000198867.31134.ac.Dingley J, Tooley J, Porter H, Thoresen M. Xenon provides shortterm neuroprotection in neonatal rats when administered after hypoxia-ischemia. Stroke. 2006;37(2):501–506. doi: 10.1161/01.STR.0000198867.31134.ac.Thoresen M, Hobbs CE, Wood T. Cooling combined with immediate or delayed xenon inhalation provides equivalent longterm neuroprotection after neonatal hypoxia-ischemia. J Cereb Blood Flow Metab. 2009;29(4):707–714. doi: 10.1038/jcbfm.2008.163.Thoresen M, Hobbs CE, Wood T. Cooling combined with immediate or delayed xenon inhalation provides equivalent longterm neuroprotection after neonatal hypoxia-ischemia. J Cereb Blood Flow Metab. 2009;29(4):707–714. doi: 10.1038/jcbfm.2008.163.Kelen D, Robertson NJ. Experimental treatments for hypoxic ischaemic encephalopathy. Early Hum Dev. 2010;86(6):369–377. doi: 10.1016/j.earlhumdev.2010.05.011.Kelen D, Robertson NJ. Experimental treatments for hypoxic ischaemic encephalopathy. Early Hum Dev. 2010;86(6):369–377. doi: 10.1016/j.earlhumdev.2010.05.011.Ma D, Hossain M, Chow A, et al. Xenon and hypothermia combine to provide neuroprotection from neonatal asphyxia. Ann Neurol. 2005;58(2):182–193. doi: 10.1002/ana.20547.Ma D, Hossain M, Chow A, et al. Xenon and hypothermia combine to provide neuroprotection from neonatal asphyxia. Ann Neurol. 2005;58(2):182–193. doi: 10.1002/ana.20547.Sabir H, Osredkar D, Maes E, et al. Xenon combined with therapeutic hypothermia is not neuroprotective after severe hypoxiaischemia in neonatal rats. PLoS One. 2016;11(6):e0156759. doi: 10.1371/journal.pone.0156759.Sabir H, Osredkar D, Maes E, et al. Xenon combined with therapeutic hypothermia is not neuroprotective after severe hypoxiaischemia in neonatal rats. PLoS One. 2016;11(6):e0156759. doi: 10.1371/journal.pone.0156759.Campos-Pires R, Armstrong SP, Sebastiani A, et al. Xenon improves neurological outcome and reduces secondary injury following trauma in an in vivo model of traumatic brain injury. Crit Care Med. 2015;43(1):149–158. doi: 10.1097/CCM.0000000000000624.Campos-Pires R, Armstrong SP, Sebastiani A, et al. Xenon improves neurological outcome and reduces secondary injury following trauma in an in vivo model of traumatic brain injury. Crit Care Med. 2015;43(1):149–158. doi: 10.1097/CCM.0000000000000624.Giacalone M, Abramo A, Giunta F, Forfori F. Xenonrelated analgesia: a new target for pain treatment. Clin J Pain. 2013;29(7):639–643. doi: 10.1097/AJP.0b013e31826b12f5.Giacalone M, Abramo A, Giunta F, Forfori F. Xenonrelated analgesia: a new target for pain treatment. Clin J Pain. 2013;29(7):639–643. doi: 10.1097/AJP.0b013e31826b12f5.Мa D, Sanders RD, Halder S, et al. Xenon exerts age-independent antinociception in Fischer rats. Anesthesiology. 2004;100(5):1313– 1318. doi: 10.1097/00000542-200405000-00040.Мa D, Sanders RD, Halder S, et al. Xenon exerts age-independent antinociception in Fischer rats. Anesthesiology. 2004;100(5):1313– 1318. doi: 10.1097/00000542-200405000-00040.Буров Н.Е., Потапов В.Н., Молчанов И.В., и др. Наркоз ксеноном. Методические рекомендации [интернет]. — М.: РМАПО; 2003. C. 20. Доступно по: http://www.esus.ru/php/content.php?id=781. Ссылка активна на 12.08.2018.Burov NE, Potapov VN, Molchanov IV, et al. Narkoz ksenonom. Metodicheskie rekomendatsii [Internet]. Moscow: RMAPO; 2003. 20 s. (In Russ). Доступно по: http://www.esus.ru/php/content.php?id=781. Ссылка активна на 12.08.2018.Генов П.Г., Смирнова О.В., Тимербаев В.Х. Ксенон для послеоперационного обезболивания. А почему бы и нет? // Анестезиология и реаниматология. — 2011. — №3 — C. 74–77.Genov PG, Smirnova OV, Timerbaev VKh. Xenon for postoperative analgesia: why not? Anesteziol Reanimatol. 2011;(3):74–77. (In Russ).Патент РФ на изобретение № 2271815 от 2003 г. Буров Н.Е., Антонов А.А. Способ аутоанальгезии ксенон-кислородной смесью. Доступно по: http://allpatents.ru/patent/2271815.html. Ссылка активна на 13.09.2018.Patent RUS № 2271815 ot 2003 g. Burov N.E., Antonov A.A. Sposob autoanal’gezii ksenon-kislorodnoi smes’yu. (In Russ). Доступно по: http://allpatents.ru/patent/2271815.html. Ссылка активна на 13.09.2018.Герасимова Ю.Ю., Ермаков М.Ю. Нейропротективные эффекты субнаркотических и наркотических концентраций медицинского ксенона // Вестник совета молодых ученых и специалистов Челябинской области. — 2017. — Т.3. — №3 — С. 21–24.Gerasimova YY, Ermakov MA. Neuroprotective effects subarcticus and drug concentrations medical xenon. Vestnik soveta molodykh uchenykh i spetsialistov Chelyabinskoi oblasti. 2017;3(3):21–24. (In Russ).Meiser-Stedman R, Smith P, Glucksman E, et al. The posttraumatic stress disorder diagnosis in preschooland elementary school-age children exposed to motor vehicle accidents. Am J Psychiatry. 2008;165(10):1326–1337. doi: 10.1176/appi.ajp.2008.07081282.Meiser-Stedman R, Smith P, Glucksman E, et al. The posttraumatic stress disorder diagnosis in preschooland elementary school-age children exposed to motor vehicle accidents. Am J Psychiatry. 2008;165(10):1326–1337. doi: 10.1176/appi.ajp.2008.07081282.Scheeringa MS, Wright MJ, Hunt MP, Zeanah CH. Factors affecting the diagnosis and prediction of PTSD symptomatology in children and adolescents. Am J Psychiatry. 2006;163(4):644–651. doi: 10.1176/ajp.2006.163.4.644.Scheeringa MS, Wright MJ, Hunt MP, Zeanah CH. Factors affecting the diagnosis and prediction of PTSD symptomatology in children and adolescents. Am J Psychiatry. 2006;163(4):644–651. doi: 10.1176/ajp.2006.163.4.644.Арана Дж., Розенбаум Дж. Руководство по психофармакотерапии. / Пер. с англ. под ред. проф. С.Н. Мосолова. 4-е изд. — Москва; 2004. — 216 с.Arana Dzh, Rozenbaum Dzh. Rukovodstvo po psikhofarmakoterapii. Transl. from English ed by prof. S.N. Mosolova. 4th ed. Moscow; 2004. 216 р. (In Russ).Carlson AP, Brown AM, Zager E, et al. Xenon enhanced cerebral blood flow at 28% xenon provides uniquely safe access toquantitative, clinically useful cerebral blood flow information: a multicenter study. AJNR Am J Neuroradiol. 2011;32(7):1315–1320. doi: 10.3174/ajnr.A2522.Carlson AP, Brown AM, Zager E, et al. Xenon enhanced cerebral blood flow at 28% xenon provides uniquely safe access toquantitative, clinically useful cerebral blood flow information: a multicenter study. AJNR Am J Neuroradiol. 2011;32(7):1315–1320. doi: 10.3174/ajnr.A2522.Hemmings HC, Mantz J. Xenon and the pharmacology of fear. Anesthesiology. 2008;109(6):954–955. doi: 10.1097/ALN.0b013e31818d4964.Hemmings HC, Mantz J. Xenon and the pharmacology of fear. Anesthesiology. 2008;109(6):954–955. doi: 10.1097/ALN.0b013e31818d4964.Бубеев Ю.А., Котровская Т.И., Кальманов А.С. Ксенонкислородная газовая ингаляция для коррекции негативных последствий стресса. В сб.: Ксенон и инертные газы в медицине: Материалы конференции анестезиологов-реаниматологов медицинских учреждений МО РФ. — М.: ГВКГ им. Н.Н. Бурденко; 2008. — С. 4–9.Bubeev YuA, Kotrovskaya TI, Kal’manov AS. Ksenonkislorodnaya gazovaya ingalyatsiya dlya korrektsii negativnykh posledstvii stressa. In: Ksenon i inertnye gazy v meditsine: Materialy konferentsii anesteziologov-reanimatologov meditsinskikh uchrezhdenii MO RF. Moscow: GVKG im. N.N. Burdenko; 2008. pp. 4–9. (In Russ).Игошина Т.В. Коррекция связанных со стрессом невротических расстройств методом ингаляции субнаркотических доз ксенона в условиях санатория // Кремлевская медицина. Клинический вестник. — 2013. —№4 — С. 37–42.Igoshina TV. Correction of stress-induced neurotic disorders using inhalations with subnarcotic xenon doses in sanatorium rehabilitation. Kremlevskaya meditsina. Klinicheskii vestnik. 2013;(4):37–42. (In Russ).Давыдова Н.С., Наумов С.А., Костромитина Г.Г., и др. Кислородно-ксеноновые ингаляции в поликлинической практике // Поликлиника. — 2013. — №5–2 — С. 48–51.Davydova NS, Naumov SA, Kostromitina GG, et al. Kislorodno-ksenonovye ingalyatsii v poliklinicheskoi praktike. Poliklinika. 2013;(5–2):48– 51. (In Russ).Игошина Т.В., Счастливцева Д.В., Котровская Т.И., Бубеев Ю.А. Динамика ЭЭГ-паттернов при коррекции стресс-реакций методом ингаляции ксенона // Вестник восстановительной медицины. — 2017. — №1 — С. 116–121.Igoshina TV, Schastlivtseva DV, Kotrovskaya TI, Bubeev YA. EEG dynamics in the elimination of stress reactions by inhalation of xenon. Vestnik vosstanovitel’noi meditsiny. 2017;(1):116–121. (In Russ).Буров Н.Е., Потапов В.Н. Ксенон в медицине: очерки по истории и применению медицинского ксенона. — М.: Пульс; 2012. — C. 406.Burov NE, Potapov VN. Ksenon v meditsine: ocherki po istorii i primeneniyu meditsinskogo ksenona. Moscow: Pul’s; 2012. Р. 406. (In Russ).Dobrovolsky A, Ichim TE, Ma D, et al. Xenon in the treatment of panic disorder: an open label study. J Transl Med. 2017;15(1):137. doi: 10.1186/s12967-017-1237-1.Dobrovolsky A, Ichim TE, Ma D, et al. Xenon in the treatment of panic disorder: an open label study. J Transl Med. 2017;15(1):137. doi: 10.1186/s12967-017-1237-1.Рабинович С.А., Заводиленко А.А., Бабиков А.С. Обезболивание и седация ксенон-кислородной смесью в стоматологии // Стоматология. — 2014. — Т.93. — №2 — С. 70–73.Rabinovich SA, Zavodilenko LA, Babikov AS. Anesthesia and sedation by admixture of xenon-oxygen in dentistry. Part I. Stomatologija. 2014;93(2):70–73. (In Russ).Morandi A, Pandharipande P, Trabucchi M, et al. Understanding international differences in terminology for delirium and other types of acute brain dysfunction in critically ill patients. Intensive Care Med. 2008;34(10):1907–1915. doi: 10.1007/s00134-008-1177-6.Morandi A, Pandharipande P, Trabucchi M, et al. Understanding international differences in terminology for delirium and other types of acute brain dysfunction in critically ill patients. Intensive Care Med. 2008;34(10):1907–1915. doi: 10.1007/s00134-008-1177-6.McGuire BE, Basten CJ, Ryan CJ, Gallagher J. Intensive care unit syndrome: a dangerous misnomer. Arch Intern Med. 2000;160(7):906–909. doi: 10.1001/archinte.160.7.906.McGuire BE, Basten CJ, Ryan CJ, Gallagher J. Intensive care unit syndrome: a dangerous misnomer. Arch Intern Med. 2000;160(7):906–909. doi: 10.1001/archinte.160.7.906.Figueroa-Ramos MI, Arroyo-Novoa CM, Lee KA, et al. Sleep and delirium in ICU patients: a review of mechanisms and manifestations. Intensive Care Med. 2009;35(5):781–795. doi: 10.1007/s00134009-1397-4.Figueroa-Ramos MI, Arroyo-Novoa CM, Lee KA, et al. Sleep and delirium in ICU patients: a review of mechanisms and manifestations. Intensive Care Med. 2009;35(5):781–795. doi: 10.1007/s00134009-1397-4.Pisani MA, Murphy TE, Van Ness PH, et al. Characteristics associated with delirium in older patients in a medical intensive care unit. Arch Intern Med. 2007;167(15):1629–1634. doi: 10.1001/archinte.167.15.1629.Pisani MA, Murphy TE, Van Ness PH, et al. Characteristics associated with delirium in older patients in a medical intensive care unit. Arch Intern Med. 2007;167(15):1629–1634. doi: 10.1001/archinte.167.15.1629.Mirski MA, Lewin III JJ, LeDroux S, et al. Cognitive improvement during continous sedation in critically ill, awake and responsive patients: the Acute Neurological ICU Sedation Trial (ANIST). Intensive Care Med. 2010;36(9):1505–1513. doi: 10.1007/s00134-0101874-9.Mirski MA, Lewin III JJ, LeDroux S, et al. Cognitive improvement during continous sedation in critically ill, awake and responsive patients: the Acute Neurological ICU Sedation Trial (ANIST). Intensive Care Med. 2010;36(9):1505–1513. doi: 10.1007/s00134-0101874-9.Цыганков Б.Д., Шамов С.А., Рыхлецкий П.З., Давлетов Л.А. Возможности применения ксенона в комплексной терапии психопатологических расстройств у больных наркологического профиля // Российский медицинский журнал. — 2013. — №4 —С. 11–14.Tzigankov BD, Shamov SA, Rykhletskiy PZ, Davletov LA. The possibilities of xenon application in complex therapy of psychopathologic disorders in patients of narcologic profile. Russian medical journal. 2013;(4):11–14. (In Russ).Sidenvall R, Johannessen S, Blennow G, et al. Epidemiology. In: Paediatric epilepsy. Sillanpaa M, Johannessen S, Blennow G, Dam M, eds. Petersfield; 1990. P. 1–8.Sidenvall R, Johannessen S, Blennow G, et al. Epidemiology. In: Paediatric epilepsy. Sillanpaa M, Johannessen S, Blennow G, Dam M, eds. Petersfield; 1990. P. 1–8.Shields WD, Duchowny MS, Holmes GL. Surgically remediable syndromes of infancy and early childhood. In: Surgical treatment of epilepsies. Engel J Jr, ed. 2d ed. N.Y.: Raven Pres; 1993. P. 35–48.Shields WD, Duchowny MS, Holmes GL. Surgically remediable syndromes of infancy and early childhood. In: Surgical treatment of epilepsies. Engel J Jr, ed. 2d ed. N.Y.: Raven Pres; 1993. P. 35–48.Keogan M, McMackin D, Peng S, et al. Temporal neocorticectomy in the management of intractable epilepsy: long-term outcome and predictive factors. Epilepsia. 1992;33(5):852–861. doi: 10.1111/j.1528-1157.1992.tb02193.x.Keogan M, McMackin D, Peng S, et al. Temporal neocorticectomy in the management of intractable epilepsy: long-term outcome and predictive factors. Epilepsia. 1992;33(5):852–861. doi: 10.1111/j.1528-1157.1992.tb02193.x.Olivier A. Surgery of extratemporal epilepsy. In: The treatment of epilepsy: principles and practice. Wyllie E, ed. 2d ed. Baltimore: Williams and Wilkins; 1997. P. 1060–1073.Olivier A. Surgery of extratemporal epilepsy. In: The treatment of epilepsy: principles and practice. Wyllie E, ed. 2d ed. Baltimore: Williams and Wilkins; 1997. P. 1060–1073.Murphy JV. Left vagal nerve stimulation in children with medically refractory epilepsy. The Pediatric VNS Study Group. J Pediatr. 1999;134(5):563–566. doi: 10.1016/s0022-3476(99)70241-6.Murphy JV. Left vagal nerve stimulation in children with medically refractory epilepsy. The Pediatric VNS Study Group. J Pediatr. 1999;134(5):563–566. doi: 10.1016/s0022-3476(99)70241-6.Ананьев В.Н. Рецепторные механизмы действия нейтральных газов на поглощение кислорода организмом // Фундаментальные исследования. — 2013. — №11–1 — С. 11–16.Ananev VN. Receptor mechanisms of neutral gas in oxygen consumption. Fundamental’nye issledovaniya. 2013;(11–1):11–16. (In Russ).Xenon pharmaceuticals advances second proprietary epilepsy product into the clinic with initiation of XEN901 phase 1 clinical trial [Elektronnyi resurs]. Available from: . Ссылка активна на 01.08.2018.Xenon pharmaceuticals advances second proprietary epilepsy product into the clinic with initiation of XEN901 phase 1 clinical trial [Elektronnyi resurs]. Available from: . Ссылка активна на 01.08.2018.Потапов В.Н., Потапов А.В., Коробов А.В., и др. Научные предпосылки при разработке новых лекарственных форм на основе ксенона марки «КсеМед». В сб.: Ксенон и инертные газы в медицине: Материалы конференции анестезиологов-реаниматологов медицинских учреждений МО РФ. — М.: ГВКГ им. Н.Н. Бурденко; 2008. — С. 106–118.Potapov VN, Potapov AV, Korobov AV, et al. Nauchnye predposylki pri razrabotke novykh lekarstvennykh form na osnove ksenona marki «KseMed». In: Ksenon i inertnye gazy v meditsine: Materialy konferentsii anesteziologov-reanimatologov meditsinskikh uchrezhdenii MO RF. Moscow: GVKG im. N.N. Burdenko; 2008. pp. 106–118. (In Russ).Николаев Л.Л., Буров Н.Е., Потапов В.Н., и др. Применение сливочных и масляных ксеноновых коктейлей у онкологических больных. В сб.: Ксенон и инертные газы в медицине: Материалы конференции анестезиологов-реаниматологов медицинских учреждений МО РФ. — М.: ГВКГ им. Н.Н. Бурденко; 2008. — С. 79–86.Nikolaev LL, Burov NE, Potapov VN, et al. Primenenie slivochnykh i maslyanykh ksenonovykh koktejlei u onkologicheskikh bol’nykh. In: Ksenon i inertnye gazy v meditsine: Materialy konferentsii anesteziologov-reanimatologov meditsinskikh uchrezhdenii MO RF. Moscow: GVKG im. N.N. Burdenko; 2008. pp. 79–86. (In Russ).

The authors declare that there are no conflicts of interest present.